Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel
O. Ortmann, O. Pagani, A. Jones, N. Maass, D. Noss, H. Rugo, C. van de Velde, Matti Aapro, R. Coleman
20110301
2011 Apr 1
Cancer Treat Rev
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel
Cancer Treat Rev. 2011 Apr;37(2):97-104, O. Ortmann, O. Pagani, A. Jones, N. Maass, D. Noss, H. Rugo, C. van de Velde, Matti Aapro, R. Coleman
Abstract
Abstract
Menopausal status is a major consideration in adjuvant breast cancer therapy. The variable onset and duration of the menopausal transition and the poor predictive value of bleeding patterns and hormone levels mean many women fall naturally into a “perimenopausal” category. Women becoming amenorrhoeic during cytotoxic or endocrine treatment are also of uncertain status since ovarian function may resume even in older patients after several months without menses. The recent St. Gallen panel acknowledged...
